AB LABS AWARDED SALES LICENSE
March 22 2019 - 9:57AM
INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company")
(TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce
that the Company’s licensed producer AB Labs Inc. (“AB Labs") has
received a medical sales and processing license from Health Canada
effective March 16, 2019, pursuant to the Cannabis Act and Cannabis
Regulations (“CACR”). The newly awarded license allows for the sale
of final packaged flower, plants and seeds to retailers,
distributers and patients.AB Labs, located in Hamilton, Ontario is
at the heart of the Company’s presence in Eastern Canada, with its
16,000 square foot Phase 1 facility currently operating at full
capacity, and its 40,000 square foot Phase 2 facility just weeks
away from finalizing its Confirmation of Readiness submission to
Health Canada. AB Labs’ research and development is also ongoing,
with fifteen new strains expected to be added to Invictus’ product
portfolio this year. “We are proud to have achieved another
major milestone with our third sales license awarded by Health
Canada,” said George E. Kveton, President and CEO of Invictus. “We
are looking forward to increasing our capacity at facilities across
Canada in 2019 to ensure a consistent and substantial supply of
products for recreational and medical patients alike.”AB Labs
represents the Company's third cultivation license and third sales
license issued by Health Canada under the Cannabis Act and Cannabis
Regulations. Invictus' production footprint includes licensed
cannabis operations in British Columbia, Alberta and Ontario.
For more information, please visit www.invictus-md.com.
On Behalf of the Board,George E. KvetonChief Executive Officer
and Director
Jessica MartinVice President, Public Relations and Regulatory
Affairs(833) 879-4363About Invictus
Invictus is a global cannabis company offering a selection of
products under a wide range of brands. Our integrated sales
approach is defined by five pillars of distribution including
medical, adult-use, international, Licensed Producer to Licensed
Producer and retail stores.
Invictus has partnered with business leaders to convey our
corporate vision, including KISS music legend and business mogul
Gene Simmons as our Chief Evangelist Officer. To meet growing
demand, Invictus is expanding its cultivation footprint, with three
cannabis production facilities licensed under the Cannabis Act and
Cannabis Regulations in Canada. To accommodate international sales,
Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd. (“Acreage
Pharms”), has designed and is currently building its Phase 3
purpose-built cultivation facility to be European Union Good
Manufacturing Practices (“EU-GMP”) compliant. The Company is
targeting up to 50 percent of production to medical cannabis. To
ensure consistency in quality and supply, Invictus maintains all
aspects of the growing process through its subsidiary, Future
Harvest Development Ltd. (“Future Harvest”), a high-quality
fertilizer and nutrients manufacturer. Invictus drives sustainable
long-term shareholder value through a diversified product portfolio
with over 70 Health Canada approved strains and a multifaceted
distribution strategy including medical, adult-use, international,
Licensed Producer to Licensed Producer and retail stores. For more
information visit www.invictus-md.com.
Cautionary Note Regarding Forward-Looking Statements: This
release includes certain statements and information that may
constitute forward-looking information within the meaning of
applicable Canadian securities laws or forward-looking statements
within the meaning of the United States Private Securities
Litigation Reform Act of 1995. All statements in this news release,
other than statements of historical facts, including statements
regarding future estimates, plans, objectives, timing, assumptions
or expectations of future performance, including the AB Labs Phase
2 facility is anticipated to be weeks away from submitting its
Confirmation of Readiness to Health Canada and that AB Labs is
expected to add 15 new strains of cannabis to the Company’s product
portfolio this year are forward-looking statements and contain
forward-looking information. Generally, forward-looking statements
and information can be identified by the use of forward-looking
terminology such as "intends" or "anticipates", or variations of
such words and phrases or statements that certain actions, events
or results "may", "could", "should", "would" or "occur".
Forward-looking statements are based on certain material
assumptions and analysis made by the Company and the opinions and
estimates of management as of the date of this press release,
including that the AB Labs Phase 2 facility is weeks away from
submitting its Confirmation of Readiness to Health Canada and that
AB Labs will add 15 new strains of cannabis to the Company’s
product portfolio this year. These forward-looking statements are
subject to known and unknown risks, uncertainties and other factors
that may cause the actual results, level of activity, performance
or achievements of the Company to be materially different from
those expressed or implied by such forward-looking statements or
forward-looking information. Important factors that may cause
actual results to vary, include, without limitation, that the AB
Labs Phase 2 facility will not submit its Confirmation of Readiness
to Health Canada on the timeline anticipated by management or at
all and that AB Labs will not add 15 new strains of cannabis to the
Company’s product portfolio this year or at all. Although
management of the Company has attempted to identify important
factors that could cause actual results to differ materially from
those contained in forward-looking statements or forward-looking
information, there may be other factors that cause results not to
be as anticipated, estimated or intended. There can be no assurance
that such statements will prove to be accurate, as actual results
and future events could differ materially from those anticipated in
such statements. Accordingly, readers should not place undue
reliance on forward-looking statements and forward-looking
information. Readers are cautioned that reliance on such
information may not be appropriate for other purposes. The Company
does not undertake to update any forward-looking statement,
forward-looking information or financial out-look that are
incorporated by reference herein, except in accordance with
applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
Jessica Martin
Invictus
(833) 879-4363
jessica@invictus-md.com
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart
From Apr 2023 to Apr 2024